Core Viewpoint - Kang En Bei announced that its wholly-owned subsidiary, Zhejiang Jinhua Kang En Bei Biopharmaceutical Co., Ltd., has received the drug registration certificate for Esomeprazole Magnesium Enteric-coated Capsules in 20mg and 40mg specifications from the National Medical Products Administration [1] Group 1: Product Information - Esomeprazole Magnesium Enteric-coated Capsules (Nexium) is the first proton pump inhibitor developed by AstraZeneca that contains a single optical isomer [1] - Nexium was launched in the United States in 2001 and approved for entry into China in 2007, effectively inhibiting gastric acid secretion [1] - The drug is primarily used for treating gastroesophageal reflux disease, erosive reflux esophagitis, and in combination with appropriate antibiotics to eradicate Helicobacter pylori, promoting the healing of related peptic ulcers [1]

Core Viewpoint - Company Zhejiang Jinhua Kang En Bei Biopharmaceutical Co., Ltd., a wholly-owned subsidiary of Kang En Bei (600572.SH), has received approval from the National Medical Products Administration for the registration of Esomeprazole Magnesium Enteric-coated Capsules in specifications of 20mg and 40mg [1] Group 1: Product Information - Esomeprazole Magnesium Enteric-coated Capsules, known as "Nexium," is the first proton pump inhibitor developed by AstraZeneca that features a single optical isomer [1] - Nexium was launched in the United States in 2001 and received approval for entry into China in 2007, effectively inhibiting gastric acid secretion [1] - The drug is primarily used in clinical settings for the treatment of gastroesophageal reflux disease, erosive reflux esophagitis, and in combination with appropriate antibiotics to eradicate Helicobacter pylori, thereby promoting the healing of related digestive ulcers [1]